BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 24113159)

  • 1. Pituitary apoplexy associated with cabergoline therapy.
    Chng E; Dalan R
    J Clin Neurosci; 2013 Dec; 20(12):1637-43. PubMed ID: 24113159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline.
    Balarini Lima GA; Machado Ede O; Dos Santos Silva CM; Filho PN; Gadelha MR
    Pituitary; 2008; 11(3):287-92. PubMed ID: 17570067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
    Delgrange E; Maiter D; Donckier J
    Eur J Endocrinol; 1996 Apr; 134(4):454-6. PubMed ID: 8640297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report.
    Kawabata Y; Ueno Y; Horikawa F; Miyake H; Miki N; Ono M
    Surg Neurol; 2008 Jan; 69(1):85-8; discussion 88. PubMed ID: 17967478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.
    Elenkova A; Shabani R; Kalinov K; Zacharieva S
    Eur J Endocrinol; 2012 Jul; 167(1):17-25. PubMed ID: 22511808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transsphenoidal surgery for a life-threatening prolactinoma apoplexy during pregnancy.
    Witek P; Zieliński G; Maksymowicz M; Zgliczyński W
    Neuro Endocrinol Lett; 2012; 33(5):483-8. PubMed ID: 23090264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma.
    Raverot G; Jacob M; Jouanneau E; Delemer B; Vighetto A; Pugeat M; Borson-Chazot F
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):588-92. PubMed ID: 18673461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain and optic chiasmal herniations into sella after cabergoline therapy of giant prolactinoma.
    Dhanwal DK; Sharma AK
    Pituitary; 2011 Dec; 14(4):384-7. PubMed ID: 19381817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cabergoline-induced tension pneumocephalus in a patient with giant invasive prolactinoma. Case report].
    Castro-Castro J; Torre-Eiriz JA; Pinzón-Millán A; Pastor-Zapata A
    Neurocirugia (Astur); 2011 Dec; 22(6):558-61; discussion 561. PubMed ID: 22167286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumocephalus during cabergoline treatment of an invasive macroprolactinoma.
    Jouret F; Col V
    Acta Clin Belg; 2009; 64(5):457. PubMed ID: 19999399
    [No Abstract]   [Full Text] [Related]  

  • 11. The cabergoline-resistant prolactinoma patient: new challenges.
    Molitch ME
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4643-5. PubMed ID: 19056842
    [No Abstract]   [Full Text] [Related]  

  • 12. Giant pubertal prolactinoma: Complete resolution following short term carbegoline treatment.
    Oguz A; Tuzun D; Sahin M; Gul K
    Niger J Clin Pract; 2016; 19(5):685-7. PubMed ID: 27538562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabergoline treatment in a case of macroprolactinoma after delivery.
    Falsetti L
    Acta Eur Fertil; 1995; 26(3):105-7. PubMed ID: 9098469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resolution of third nerve palsy following treatment of prolactinoma with cabergoline.
    Harries AM; Gittoes NJ; Mitchell RD
    Acta Neurochir (Wien); 2010 Oct; 152(10):1741-3. PubMed ID: 20623359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma.
    Knoepfelmacher M; Gomes MC; Melo ME; Mendonca BB
    Pituitary; 2004; 7(2):83-7. PubMed ID: 15761656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
    Kars M; Delgado V; Holman ER; Feelders RA; Smit JW; Romijn JA; Bax JJ; Pereira AM
    J Clin Endocrinol Metab; 2008 Sep; 93(9):3348-56. PubMed ID: 18559921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabergoline treatment of pregnant women with macroprolactinomas.
    Laloi-Michelin M; Ciraru-Vigneron N; Meas T
    Int J Gynaecol Obstet; 2007 Oct; 99(1):61-2. PubMed ID: 17602689
    [No Abstract]   [Full Text] [Related]  

  • 18. Pituitary Apoplexy in Long-Term Cabergoline User During Thrombocytopenia Due to Chemotherapy for Chronic Myelocytic Leukemia.
    Maki Y; Kurosaki Y; Uchino K; Ishibashi R; Chin M; Yamagata S
    World Neurosurg; 2018 Dec; 120():290-295. PubMed ID: 30189305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of a prolactin-secreting pituitary microadenoma into a fatal carcinoma: a case report.
    Guastamacchia E; Triggiani V; Tafaro E; De Tommasi A; De Tommasi C; Luzzi S; Sabbà C; Resta F; Terreni MR; Losa M
    Minerva Endocrinol; 2007 Sep; 32(3):231-6. PubMed ID: 17912159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prolactinoma and pregnancy].
    Trifonov I
    Akush Ginekol (Sofiia); 2004; 43 Suppl 2():16-22. PubMed ID: 15518268
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.